Thrombocytopenia Market

DelveInsight’s ‘Thrombocytopenia —Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the Thrombocytopenia, historical and forecasted epidemiology as well as the Thrombocytopenia market trends in the United States, EU5(Germany, France, Italy, Spain, and the United Kingdom) and Japan.


The Thrombocytopenia market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Thrombocytopenia market size from 2018 to 2030. The report also covers current Thrombocytopenia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Thrombocytopenia Disease Understanding and Treatment Algorithm

Overview

Thrombocytopenia is a condition in which the blood has a lower than a normal number of blood cell fragments called platelets. Platelets are made in the bone marrow along with other kinds of blood cells. They travel through the blood vessels and stick together (clot) to stop any bleeding that may happen if a blood vessel is damaged. Platelets also are called thrombocytes because a clot also is called a thrombus. When a patient’s blood has too few platelets, mild to serious bleeding can occur. Bleeding can occur inside the body (internal bleeding) or underneath the skin, or from the skin’s surface (external bleeding). A normal platelet count in adults ranges from 150,000 to 450,000 platelets/μL of blood. A platelet count of fewer than 150,000 platelets/μL is lower than normal. If the blood platelet count falls below normal, the patient has thrombocytopenia. However, the risk for serious bleeding does not occur until the count becomes very low—less than 10,000 or 20,000 platelets/μL. Mild bleeding sometimes occurs when the count is less than 50,000 platelets per microliter.


Many factors can cause thrombocytopenia (a low platelet count). The condition can be inherited or acquired. “Inherited” means parents pass the gene for the condition to the patient. “Acquired” means the patients are not born with the condition, but they develop it. Sometimes the cause of thrombocytopenia is not known.


Thrombocytopenia Diagnosis

The diagnostic test that may be recommended include complete blood count (CBC) with platelet count and mean platelet volume (MPV) and peripheral blood smear (PBS). Thrombocytopenia can result from decreased platelet production, increased platelet consumption, or sequestration. A systematic approach should be used to evaluate incidental thrombocytopenia. Physicians should inquire about easy bruising or petechiae, melena, rashes, fevers, and bleeding during the patient’s history. They also should inquire about medication use, immunizations, recent travel, transfusion history, family history, and medical history. A history of acute and chronic alcohol use should be obtained.


Thrombocytopenia Treatment

Treatment for thrombocytopenia depends on its cause and severity. The main goal of treatment is to prevent death and disability caused by bleeding. If the condition is mild, the patient may not need treatment. A fully normal platelet count is not necessary to prevent bleeding, even with severe cuts or accidents.


If the cause of thrombocytopenia is unknown, and there are no contraindications, such as infections, corticosteroids may be used to increase the platelet count. More specific treatment plans usually depend on the underlying etiology of thrombocytopenia.


Patients with inherited thrombocytopenia have been treated with platelet transfusions (reserved for bleeding cases or its prevention, e.g., before surgery). While the fear of sensitization has dominated the restriction of platelet transfusion, the availability of leukoreduction has greatly decreased this risk. In this case, one of the two thrombopoietin-receptor agonists, eltrombopag, was investigated ted as a possible treatment option in MYH9-related disorders. The option of allogeneic stem cell transplantation is reserved for inherited thrombocytopenias with a high risk of marrow failure or a high risk of acute leukemia.


Many cases of ITP can be left untreated, and spontaneous remission in children is common. If therapy is required, the first-line treatment option is generally corticosteroids, with the recommended prednisone dose 1 mg/kg/day orally for up to 21–28 days depending upon the response, followed by slow tapering. Also, intravenous immunoglobulin or intravenous anti-D (Rho[D] immune globulin) can be used as an initial treatment with or without steroids. The most effective second-line treatment option is splenectomy. Additional second-line treatment options with documented evidence of efficacy (allowing postponement of splenectomy) include many agents: azathioprine, cyclosporine, cyclophosphamide, danazol, dexamethasone, vinca alkaloids, mycophenolate mofetil, rituximab, and thrombopoietin-receptor agonists.


The use of thrombopoietin-receptor agonists is an effective and safe second-line treatment strategy. Two thrombopoietin-receptor agonists were approved for the treatment of chronic ITP in adults by the US Food and Drug Administration (FDA) in 2008 and have as of now been used extensively for treatment of chronic ITP (ITP duration ≥1 year) in relapsed and refractory patients. These were romiplostim, a thrombopoietin mimetic formed from peptides (peptibody), and eltrombopag (a small molecule, non-peptide).


The mainstay of treatment in TTP is plasmapheresis with plasma replacement. Other treatment modalities in non-responders to plasmapheresis include immune-suppression, not limited to high dose steroids and B-cell depleting agents (e.g., rituximab).


In the event of drug-induced thrombocytopenia/DITP, it is a universal practice to stop the suspected drug immediately. Platelet transfusions may be required to treat patients with severe thrombocytopenia and bleeding. Other supportive measures include high dose intravenous immunoglobulin, a brief course of corticosteroids, or even plasmapheresis.

Thrombocytopenia Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Cases of Thrombotic Thrombocytopenic Purpura (TTP), Prevalent Cases of Immune Thrombocytopenia (ITP), Prevalent Cases of Thrombocytopenia in Chronic Liver Disease, Incident Cases of Chemotherapy-induced Thrombocytopenia, Number of Cases of Heparin-induced Thrombocytopenia and Total Cases of Thrombocytopenia scenario of Thrombocytopenia in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2018 to 2030.


Key Findings

  • This section provides glimpses of the Thrombocytopenia epidemiology in the 7MM.
  • As per DelveInsight analysis, the total number of cases of Thrombocytopenia in the 7MM was 1,653,934 in 2020. These cases of Thrombocytopenia in the 7MM are expected to increase throughout the study period i.e. 2018–2030, with CAGR of 0.66% for the study period 2018–2030.
  • As per DelveInsight analysis, the United States accounted for the highest number of Thrombocytopenia cases among the 7MM. The total number of Thrombocytopenia cases in the US was estimated to be 467,078 in 2020.
  • In 2020, the prevalent population of Thrombotic Thrombocytopenia in the United States was 6,002 which are expected to rise with the CAGR of 0.79% for the study period 2018–2030.
  • In 2020, there were 66,708 prevalent cases of Immune thrombocytopenia (ITP) in the United States.
  • Germany ranked second-highest for Thrombocytopenia cases among 7MM. In 2020, Germany had 325,202 Thrombocytopenia cases.
  • Among the European 5 countries, Germany had the highest cases of Thrombocytopenia with 325,202 cases, followed by the United Kingdom and Spain, with 230,597 cases and 182,796 cases, respectively. On the other hand, Italy had the lowest cases, i.e., 102,933 in 2020.
  • As per DelveInsight analysis, Japan accounted for the fourth-highest number of Thrombocytopenia cases among the 7MM. The total number of Thrombocytopenia cases in Japan was estimated to be 219,017 in 2020.

Country Wise-Thrombocytopenia Epidemiology

The epidemiology segment also provides the Thrombocytopenia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Thrombocytopenia Drug Chapters

This segment of the Thrombocytopenia report encloses the detailed analysis of the marketed and pipeline drugs/devices. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.


Thrombocytopenia Marketed Products


Cablivi (Caplacizumab/ALX-0081): Sanofi (Ablynx)

Cablivi is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy. It is approved in the US and EU for the treatment of aTTP. A Phase II/III trial is ongoing in Japan for the same indication. Cablivi was approved in the European Union in August 2018. The US FDA approved the drug in February 2019 for the treatment of aTTP. The drug is also marketed in Germany, Denmark, Italy, and Finland and is available in France under a temporary user license.

Products detail in the report…


Tavalisse (Fostamatinib): Rigel Pharmaceuticals/Kissei Pharmaceutical

Fostamatinib disodium (also known as Tavalisse; R-985788) is an orally-bioavailable investigational agent being developed by Rigel pharmaceuticals and approved for the treatment of patients suffering from persistent/chronic adult idiopathic thrombocytopenic purpura. The therapeutic candidate inhibits FcR-triggered, Syk-dependent cytoskeletal rearrangement during phagocytosis. As stated by Rigel Pharmaceuticals, fostamatinib has a unique mechanism of action, blocking IgG receptor signaling in both macrophages and B cells via SYK kinase. In April 2018, the US FDA approved Tavalisse (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. In July 2020, Rigel Pharmaceuticals announced that Grifols, its collaborative partner in Europe, had launched Tavalisse in Germany and the United Kingdom.

Products detail in the report…

List to be continued in the report…


Thrombocytopenia Emerging Therapies


Rozanolixizumab (UCB7665): UCB Biopharma

Rozanolixizumab (also known as UCB7665) is UCB Biopharma’s intravenously and subcutaneously administered, investigational humanized monoclonal IgG antibody being developed by UCB for the treatment of idiopathic thrombocytopenic purpura and myasthenia gravis (MG). The body’s immune system produces antibodies that normally help fight off infections and threats. In MG patients, pathogenic IgG autoantibodies mistakenly attack healthy cells and tissues, causing weakness and voluntary muscle fatigue. High concentrations of pathogenic IgG autoantibodies in the circulation occur due to the action of the neonatal Fc receptor (FcRn) that bind to IgG, inhibiting its degradation. Rozanolixizumab works by binding with high affinity to human neonatal Fc receptor (FcRn), selectively inhibiting IgG rescue and recycling. The company is currently evaluating this molecule in the phase III stage of development in subjects with primary immune thrombocytopenia (ITP). The company expects topline the phase III trial results by the second half of 2022.

Products detail in the report…


Rilzabrutinib (PRN-1008): Principia Biopharma

Rilzabrutinib (PRN-1008) is an orally administered reversible covalent inhibitor of Bruton Tyrosine Kinase (BTK). BTK is an essential signaling element downstream of the B cell receptor (BCR), Fc-gamma receptor, and Fc-epsilon receptor pathways. BTK activation is critical for B cell activation and maturation.


BTK also regulates antibody-mediated activation of other immune cells, such as macrophages, neutrophils, and mast cells through Fc receptor signaling.The drug candidate is a fast-acting, orally available therapy that could effectively and safely modulate B-cell function without depleting the B-cells and is expected to be a major advancement in treating autoimmune and inflammatory diseases. PNR-1008 is under development by Principia Biopharma and is currently in the phase III stage of development to treat Immune Thrombocytopenia in adults and adolescents with persistent or chronic immune thrombocytopenia (ITP).

Products detail in the report…

List to be continued in the report…

Thrombocytopenia Market Outlook

Treatment for thrombocytopenia depends on its cause and severity. The main goal of treatment is to prevent death and disability caused by bleeding. If the condition is mild, the patient may not need treatment. A fully normal platelet count is not necessary to prevent bleeding, even with severe cuts or accidents.


If the cause of thrombocytopenia is unknown, and there are no contraindications, such as infections, corticosteroids may be used to increase the platelet count. More specific treatment plans usually depend on the underlying etiology of thrombocytopenia.


Patients with inherited thrombocytopenia have been treated with platelet transfusions (reserved for bleeding cases or its prevention, e.g., before surgery). While the fear of sensitization has dominated the restriction of platelet transfusion, the availability of leukoreduction has greatly decreased this risk. In this case, one of the two thrombopoietin-receptor agonists, eltrombopag, was investigated ted as a possible treatment option in MYH9-related disorders. The option of allogeneic stem cell transplantation is reserved for inherited thrombocytopenias with a high risk of marrow failure or a high risk of acute leukemia.


Many cases of ITP can be left untreated, and spontaneous remission in children is common. If therapy is required, the first-line treatment option is generally corticosteroids, with the recommended prednisone dose 1 mg/kg/day orally for up to 21–28 days depending upon the response, followed by slow tapering. Also, intravenous immunoglobulin or intravenous anti-D (Rho[D] immune globulin) can be used as an initial treatment with or without steroids. The most effective second-line treatment option is splenectomy. Additional second-line treatment options with documented evidence of efficacy (allowing postponement of splenectomy) include many agents: azathioprine, cyclosporine, cyclophosphamide, danazol, dexamethasone, vinca alkaloids, mycophenolate mofetil, rituximab, and thrombopoietin-receptor agonists.


The use of thrombopoietin-receptor agonists is an effective and safe second-line treatment strategy. Two thrombopoietin-receptor agonists were approved for the treatment of chronic ITP in adults by the US Food and Drug Administration (FDA) in 2008 and have as of now been used extensively for treatment of chronic ITP (ITP duration ≥1 year) in relapsed and refractory patients. These were romiplostim, a thrombopoietin mimetic formed from peptides (peptibody) and eltrombopag (a small molecule, non-peptide).

According to DelveInsight, the Thrombocytopenia market is expected to change in the study period 2018–2030.


Key Findings

This section includes a glimpse of the Thrombocytopenia 7MM market.

  • The market size of Thrombocytopenia in the seven major markets was USD 4,142.40 million in 2020 which is expected to grow at a CAGR of 4.69%, for the study period of 2018–2030.
  • The market size of Thrombocytopenia in the US was USD 2,327.88 million in 2020.
  • Among the EU5 countries, the UK had the highest market size with USD 391.79 million in 2020, while France had the lowest market size of Thrombocytopenia with USD 215.47 million in 2020.
  • The United States accounts for the highest market size of Thrombocytopenia, in comparison to the other major markets i.e., EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
  • With the expected launch of upcoming therapies, Rozanolixizumab (UCB7665); Rilzabrutinib (PRN-1008); BAX930; Efgartigimod (ARGX-113); Cablivi (caplacizumab); Tavalisse/Tavlesse (Fostamatinib); Doptelet (Avatrombopag); Nplate (Romiplostim)-for CIT; and Mulpleta (lusutrombopag), the market might experience a significant growth.
  • According to DelveInsight’s analysis, for ITP, the market of current treatment includes TPO-RAs (Nplate (Romiplostim); Promacta (eltrombopag), which generated the revenue of nearly USD 642.98 million and USD 751.44 million in 2020.


Market Outlook for Seven Major Markets

This section provides the total Thrombocytopenia market size and market size by therapies in the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.

Thrombocytopenia Drugs Uptake

This section focuses on the rate of uptake of the potential drugs that are expected to get launched in the market during the study period 2018–2030. The analysis covers Thrombocytopenia market uptake by drugs; patient uptake by therapies; and sales of each drug.


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Thrombocytopenia Development Activities

The report provides insights into different therapeutic candidates in the clinical and premarket clinical studies. It also analyzes key players involved in developing targeted therapeutics.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Thrombocytopenia emerging therapies.

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Thrombocytopenia market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Thrombocytopenia, explaining its causes, symptoms, diagnosis, and currently available therapies.
  • Comprehensive insight has been provided into the Thrombocytopenia epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Thrombocytopenia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Thrombocytopenia market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM Thrombocytopenia market.

Report Highlights

  • The thrombocytopenia market is anticipated to increase for the study period 2018–2030.
  • In the coming years, the Thrombocytopenia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Thrombocytopenia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Thrombocytopenia. The expected launch of emerging therapies will significantly impact the Thrombocytopenia market.
  • Our in-depth analysis of the pipeline assets across different stages of development, different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key competitors, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Thrombocytopenia Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Thrombocytopenia Pipeline Analysis
  • Thrombocytopenia Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Thrombocytopenia Report Key Strengths

  • 10-Years Forecast
  • 7MMCoverage
  • Thrombocytopenia Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Thrombocytopenia Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT Analysis

Key Questions

Market Insights:

  • What was the Thrombocytopenia market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the Thrombocytopenia total market size as well as market size by therapies across the 7MM during the forecast period (2021–2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Thrombocytopenia market size during the forecast period (2021–2030)?
  • At what CAGR, the Thrombocytopenia market is expected to grow at the 7MM level during the forecast period (2021–2030)?
  • What would be the Thrombocytopenia market outlook across the 7MM during the forecast period (2021–2030)?
  • What would be the Thrombocytopenia market growth until 2030, and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What is the disease risk, burden, and unmet needs of Thrombocytopenia?
  • What is the historical Thrombocytopenia patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What would be the forecasted patient pool of Thrombocytopenia at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Thrombocytopenia?
  • Out of the countries mentioned above, which country would have the highest number of Thrombocytopenia cases during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Thrombocytopenia along with the approved therapy?
  • What are the Thrombocytopenia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Thrombocytopenia?
  • How many therapies are developed by each company for the treatment of Thrombocytopenia?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of Thrombocytopenia?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Thrombocytopenia therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Thrombocytopenia and their status?
  • What are the key designations that have been granted for the emerging therapies for Thrombocytopenia?
  • What are the 7MM historical and forecasted market of Thrombocytopenia?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Thrombocytopenia.
  • To understand the future market competition in the Thrombocytopenia market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Thrombocytopenia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Thrombocytopenia market.
  • To understand the future market competition in the Thrombocytopenia market.


1. Key Insights

2. Executive Summary of Thrombocytopenia

3. Thrombocytopenia Market Overview at a Glance

3.1. Market Share (%) Distribution of Thrombocytopenia in 2018

3.2. Market Share (%) Distribution of Thrombocytopenia in 2030

4. Thrombocytopenia: Disease Background and Overview

4.1. Introduction

4.2. Causes of Thrombocytopenia

4.2.1. Emergent Thrombocytopenia

4.2.2. Non-emergent Thrombocytopenia

4.3. Symptoms of Thrombocytopenia

4.4. Diagnosis of Thrombocytopenia

4.4.1. Chemotherapy-induced thrombocytopenia (CIT)

4.4.2. Immune thrombocytopenic purpura

4.4.3. Heparin-induced Thrombocytopenia

4.4.4. Thrombocytopenia associated with Chronic Liver

4.4.5. Thrombotic thrombocytopenic purpura

4.5. Diagnostic Guidelines of Thrombocytopenia

4.5.1. Clinical Practice Guideline on the Evaluation and Management of Immune Thrombocytopenia (ITP)

4.5.2. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura (TTP)

4.5.3. Guidelines on the diagnosis of heparin-induced thrombocytopenia (HIT): second edition

5. Patient Journey

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Epidemiology Methodology

6.3. 7MM Total Prevalent Patient Population of Thrombocytopenia

7. Country Wise-Epidemiology of Thrombocytopenia

7.1. United States Epidemiology

7.1.1. Assumptions and Rationale

7.1.2. Prevalent Cases of Thrombotic Thrombocytopenic Purpura (TTP) in the United States

7.1.3. Prevalent Cases of Immune Thrombocytopenia (ITP) in the United States

7.1.4. Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in the United States

7.1.5. Incident Cases of Chemotherapy-induced Thrombocytopenia in the United States

7.1.6. Number of Cases of Heparin-induced Thrombocytopenia in the United States

7.1.7. Total Cases of Thrombocytopenia in the United States

7.2. EU5 Epidemiology

7.2.1. Germany

7.2.1.1. Assumptions and Rationale

7.2.1.2. Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Germany

7.2.1.3. Prevalent Cases of Immune Thrombocytopenia in Germany

7.2.1.4. Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Germany

7.2.1.5. Incidence Cases of Chemotherapy-induced Thrombocytopenia in Germany

7.2.1.6. Number of Cases of Heparin-induced Thrombocytopenia in Germany

7.2.1.7. Total Cases of Thrombocytopenia in Germany

7.2.2. France

7.2.2.1. Assumptions and Rationale

7.2.2.2. Prevalent Cases of Thrombotic Thrombocytopenic Purpura in France

7.2.2.3. Prevalent Cases of Immune Thrombocytopenia in France

7.2.2.4. Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in France

7.2.2.5. Incidence Cases of Chemotherapy-induced Thrombocytopenia in France

7.2.2.6. Number of Cases of Heparin-induced Thrombocytopenia in France

7.2.2.7. Total Cases of Thrombocytopenia in France

7.2.3. Italy

7.2.3.1. Assumptions and Rationale

7.2.3.2. Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Italy

7.2.3.3. Prevalent Cases of Immune Thrombocytopenia in Italy

7.2.3.4. Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Italy

7.2.3.5. Incidence Cases of Chemotherapy-induced Thrombocytopenia in Italy

7.2.3.6. Number of Cases of Heparin-induced Thrombocytopenia in Italy

7.2.3.7. Total Cases of Thrombocytopenia in Italy

7.2.4. Spain

7.2.4.1. Assumptions and Rationale

7.2.4.2. Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Spain

7.2.4.3. Prevalent Cases of Immune Thrombocytopenia in Spain

7.2.4.4. Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Spain

7.2.4.5. Incidence Cases of Chemotherapy-induced Thrombocytopenia in Spain

7.2.4.6. Number of Cases of Heparin-induced Thrombocytopenia in Spain

7.2.4.7. Total Cases of Thrombocytopenia in Spain

7.2.5. United Kingdom

7.2.5.1. Assumptions and Rationale

7.2.5.2. Prevalent Cases of Thrombotic Thrombocytopenic Purpura in the UK

7.2.5.3. Prevalent Cases of Immune Thrombocytopenia in the UK

7.2.5.4. Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in the UK

7.2.5.5. Incidence Cases of Chemotherapy-induced Thrombocytopenia in the UK

7.2.5.6. Number of Cases of Heparin-induced Thrombocytopenia in the UK

7.2.5.7. Total Cases of Thrombocytopenia in the UK

7.3. Japan Epidemiology

7.3.1. Assumptions and Rationale

7.3.2. Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Japan

7.3.3. Prevalent Cases of Immune Thrombocytopenia in Japan

7.3.4. Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Japan

7.3.5. Incidence Cases of Chemotherapy-induced Thrombocytopenia in Japan

7.3.6. Number of Cases of Heparin-induced Thrombocytopenia in Japan

7.3.7. Total Cases of Thrombocytopenia in Japan

8. Treatment of Thrombocytopenia

8.1. Etiology-specific treatment

8.1.1. Inherited thrombocytopenia

8.1.2. Immune thrombocytopenia (ITP)

8.1.3. Thrombotic thrombocytopenic purpura

8.1.4. Drug-induced thrombocytopenia/DITP and heparin-induced thrombocytopenia

8.1.5. Thrombocytopenia in pregnancy

8.2. Treatment Guidelines of Thrombocytopenia

8.2.1. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition

8.2.2. American Society of Hematology (ASH) 2019 guidelines for immune thrombocytopenia

9. Unmet Needs

10. Marketed Drugs

10.1. Cablivi (Caplacizumab/ALX-0081): Sanofi (Ablynx)

10.1.1. Drug Description

10.1.2. Regulatory Milestones

10.1.3. Clinical Development

10.1.4. Clinical Trial Information

10.1.5. Safety and Efficacy

10.1.6. Product Profile

10.2. Tavalisse (Fostamatinib): Rigel Pharmaceuticals/Kissei Pharmaceutical

10.2.1. Drug Description

10.2.2. Regulatory Milestones

10.2.3. Clinical Development

10.2.4. Clinical Trial Information

10.2.5. Safety and Efficacy

10.2.6. Product Profile

10.3. Doptelet (Avatrombopag): Sobi (Dova Pharmaceuticals)

10.3.1. Drug Description

10.3.2. Regulatory Milestones

10.3.3. Clinical Development

10.3.4. Clinical Trial Information

10.3.5. Safety and Efficacy

10.3.6. Product Profile

10.4. Mulpleta/Mulpleo (Lusutrombopag): Shionogi & Co., Ltd.

10.4.1. Drug Description

10.4.2. Regulatory Milestones

10.4.3. Clinical Development

10.4.4. Clinical Trials Information

10.4.5. Safety and Efficacy

10.4.6. Product Profile

10.5. Nplate (Romiplostim, AMG-531): Amgen

10.5.1. Drug Description

10.5.2. Regulatory Milestones

10.5.3. Clinical Development

10.5.4. Clinical Trials Information

10.5.5. Safety and Efficacy

10.5.6 Product Profile

10.6. Promacta (eltrombopag): Novartis

10.6.1. Drug Description

10.6.2. Regulatory Milestones

10.6.3. Clinical Development

10.6.4. Clinical Trials Information

10.6.5. Safety and Efficacy

10.6.6. Product Profile

10.7. Rituxan (rituximab): Zenyaku Kogyo

10.7.1. Drug Description

10.7.2. Regulatory Milestones

10.7.3. Clinical Development

10.7.4. Clinical Trials Information

10.7.5. Safety and Efficacy

10.7.6. Product Profile

11. Emerging Drugs

11.1. Key Cross Competition

11.2. Rozanolixizumab (UCB7665): UCB Biopharma

11.2.1. Product Description

11.2.2. Other Development Activities

11.2.3. Clinical Development

11.2.4. Clinical Trials Information

11.2.5. Safety and efficacy

11.2.6. Product Profile

11.3. Rilzabrutinib (PRN-1008): Principia Biopharma

11.3.1. Drug Description

11.3.2. Other Development Activities

11.3.3. Clinical Development

11.3.4. Clinical Trials Information

11.3.5. Safety and Efficacy

11.3.6. Product Profile

11.4. TAK-755 (BAX930/SHP655): Baxalta/Takeda

11.4.1. Product Description

11.4.2. Other Developmental Activities

11.4.3. Clinical Development

11.4.4. Clinical Trials Information

11.4.5. Safety and Efficacy

11.4.6. Product Profile

11.5. Efgartigimod (ARGX-113): Argenx

11.5.1. Product Description

11.5.2. Other Development Activities

11.5.3. Clinical Development

11.5.4. Clinical Trials Information

11.5.5. Safety and efficacy

11.5.6. Product Profile

11.6. GC5101B (GC5107A, IV-Globulin SN Inj. 10%): GC Pharma

11.6.1. Product Description

11.6.2. Other Developmental Activities

11.6.3. Clinical Development

11.6.4. Clinical Trials Information

11.6.5. Safety and Efficacy

11.6.6. Product Profile

11.7. Narsoplimab (OMS721): Omeros Corporation

11.7.1. Product Description

11.7.2. Other Developmental Activities

11.7.3. Clinical Development

11.7.4. Clinical Trials Information

11.7.5. Safety and Efficacy

11.7.6. Product Profile

11.8. BT-595: Biotest

11.8.1. Drug Description

11.8.2. Other Development Activities

11.8.3. Clinical Development

11.8.4. Clinical Trials Information

11.8.5. Product Profile

11.9. TAK-079: Millennium Pharmaceuticals/Takeda

11.9.1. Product Description

11.9.2. Clinical Development

11.9.3. Clinical Trials Information

11.9.4. Product Profile

11.10. Thrombosomes: Cellphire

11.10.1. Product Description

11.10.2. Other Developmental Activities

11.10.3. Clinical Development

11.10.4. Clinical Trials Information

11.10.5. Safety and Efficacy

11.10.6. Product Profile

11.11. M254 (Hypersialylated IgG): Momenta Pharmaceuticals

11.11.1. Product Description

11.11.2. Other Developmental Activities

11.11.3. Clinical Development

11.11.4. Clinical Trials Information

11.11.5. Safety and Efficacy

11.11.6. Product Profile

11.12. BIVV020: Sanofi

11.12.1. Product Description

11.12.2. Other Developmental Activities

11.12.3. Clinical Development

11.12.4. Clinical Trials Information

11.12.5. Product Profile

11.13. Interleukin 2: ILTOO Pharma

11.13.1. Product Description

11.13.2. Other Developmental Activities

11.13.3. Clinical Development

11.13.4. Clinical Trials Information

11.13.5. Safety and Efficacy

11.13.6. Product Profile

11.14. SKI-O-703: Genosco (Subsidiary of Oscotec)

11.14.1. Product Description

11.14.2. Clinical Development

11.14.3. Clinical Trials Information

11.14.4. Product Profile

12. Thrombocytopenia: Seven Major Market Analysis

12.1. Key Findings

12.2. Market Methodology

12.3. Key Market Forecast Assumptions

12.4. Market Size of Thrombocytopenia in the 7MM

12.5. Market Size of Thrombocytopenia by Therapies in the 7MM

12.5.1. Market Size of Thrombocytopenia by Current Therapies in the 7MM

12.5.2. Market Size of Thrombocytopenia by Potential Therapies in the 7MM

13. Market Outlook: The United States

13.1. United States Market Size

13.1.1. Total Market Size of Thrombocytopenia

13.1.2. Market Size of Thrombocytopenia by Therapies in the United States

14. Market Outlook: Europe

14.1. Germany

14.1.1. Total Market size of Thrombocytopenia

14.1.2. Market Size of Thrombocytopenia by Therapies in Germany

14.2. France

14.2.1. Total Market size of Thrombocytopenia

14.2.2. Market Size of Thrombocytopenia by Therapies in France

14.3. Italy

14.3.1. Total Market size of Thrombocytopenia

14.3.2. Market Size of Thrombocytopenia by Therapies in Italy

14.4. Spain

14.4.1. Total Market size of Thrombocytopenia

14.4.2. Market Size of Thrombocytopenia by Therapies in Spain

14.5. United Kingdom

14.5.1. Total Market size of Thrombocytopenia

14.5.2. Market Size of Thrombocytopenia by Therapies in the United Kingdom

15. Market Outlook: Japan

15.1. Total Market size of Thrombocytopenia

15.2. Market Size of Thrombocytopenia by Therapies in Japan

16. Market Drivers

17. Market B

arriers

18. SWOT Analysis

19. Reimbursement and Market Access

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Table

Table 1: Summary of Thrombocytopenia, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Differential diagnosis of thrombocytopenia according to the clinical scenario

Table 3: Total Prevalent Patient Population of Thrombocytopenia in the 7MM (2018–2030)

Table 4: Prevalent Cases of Thrombotic Thrombocytopenic Purpura in the United States (2018–2030)

Table 5: Prevalent Cases of Immune Thrombocytopenia in the United States (2018–2030)

Table 6: Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in the United States (2018–2030)

Table 7: Incident Cases of Chemotherapy-induced Thrombocytopenia in the United States (2018–2030)

Table 8: Number of Cases of Heparin-induced Thrombocytopenia in the United States (2018–2030)

Table 9: Total Cases of Thrombocytopenia in the United States (2018–2030)

Table 10: Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Germany (2018–2030)

Table 11: Prevalent Cases of Immune Thrombocytopenia in Germany (2018–2030)

Table 12: Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Germany (2018–2030)

Table 13: Incidence Cases of Chemotherapy-induced Thrombocytopenia in Germany (2018–2030)

Table 14: Number of Cases of Heparin-induced Thrombocytopenia in Germany (2018–2030)

Table 15: Total Cases of Thrombocytopenia in Germany (2018–2030)

Table 16: Prevalent Cases of Thrombotic Thrombocytopenic Purpura in France (2018–2030)

Table 17: Prevalent Cases of Immune Thrombocytopenia in France (2018–2030)

Table 18: Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in France (2018–2030)

Table 19: Incidence Cases of Chemotherapy-induced Thrombocytopenia in France (2018–2030)

Table 20: Number of Cases of Heparin-induced Thrombocytopenia in France (2018–2030)

Table 21: Total Cases of Thrombocytopenia in France (2018–2030)

Table 22: Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Italy (2018–2030)

Table 23: Prevalent Cases of Immune Thrombocytopenia in Italy (2018–2030)

Table 24: Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Italy (2018–2030)

Table 25: Incidence Cases of Chemotherapy-induced Thrombocytopenia in Italy (2018–2030)

Table 26: Number of Cases of Heparin-induced Thrombocytopenia in Italy (2018–2030)

Table 27: Total Cases of Thrombocytopenia in Italy (2018–2030)

Table 28: Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Spain (2018–2030)

Table 29: Prevalent Cases of Immune Thrombocytopenia in Spain (2018–2030)

Table 30: Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Spain (2018–2030)

Table 31: Incidence Cases of Chemotherapy-induced Thrombocytopenia in Spain (2018–2030)

Table 32: Number of Cases of Heparin-induced Thrombocytopenia in Spain (2018–2030)

Table 33: Total Cases of Thrombocytopenia in Spain (2018–2030)

Table 34: Prevalent Cases of Thrombotic Thrombocytopenic Purpura in the UK (2018–2030)

Table 35: Prevalent Cases of Immune Thrombocytopenia in the UK (2018–2030)

Table 36: Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in the UK (2018–2030)

Table 37: Incidence Cases of Chemotherapy-induced Thrombocytopenia in the UK (2018–2030)

Table 38: Number of Cases of Heparin-induced Thrombocytopenia in the UK (2018–2030)

Table 39: Total Cases of Thrombocytopenia in the UK (2018–2030)

Table 40: Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Japan (2018–2030)

Table 41: Prevalent Cases of Immune Thrombocytopenia in Japan (2018–2030)

Table 42: Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Japan (2018–2030)

Table 43: Incidence Cases of Chemotherapy-induced Thrombocytopenia in Japan (2018–2030)

Table 44: Number of Cases of Heparin-induced Thrombocytopenia in Japan (2018–2030)

Table 45: Total Cases of Thrombocytopenia in Japan (2018–2030)

Table 46: Cablivi (Caplacizumab/ALX-0081), Clinical Trial Description, 2021

Table 47: Tavalisse (Fostamatinib), Clinical Trial Description, 2021

Table 48: Doptelet (Avatrombopag), Clinical Trial Description, 2021

Table 49: Lusutrombopag, Clinical Trial Description, 2021

Table 50: Nplate (Romiplostim), Clinical Trial Description, 2021

Table 51: Promacta (eltrombopag), Clinical Trial Description, 2021

Table 52: Rituxan, Clinical Trial Description, 2021

Table 53: Comparison of emerging drugs under development (Phase III)

Table 54: Comparison of emerging drugs under development ( Phase II)

Table 55: Comparison of emerging drugs under development (Phase I, Preclinical and Discovery)

Table 56: Rozanolixizumab, Clinical Trial Description, 2021

Table 57: Rilzabrutinib (PRN-1008), Clinical Trial Description, 2021

Table 58: TAK-755 (BAX930/SHP655), Clinical Trial Description, 2021

Table 59: Efgartigimod (ARGX-113), Clinical Trial Description, 2021

Table 60: GC5101B (GC5107A, IV-Globulin SN Inj. 10%), Clinical Trial Description, 2021

Table 61: Narsoplimab (OMS721), Clinical Trial Description, 2021

Table 62: BT-595, Clinical Trial Description, 2021

Table 63: TAK-079, Clinical Trial Description, 2021

Table 64: Thrombosomes, Clinical Trial Description, 2021

Table 65: M254, Clinical Trial Description, 2021

Table 66: BIVV020, Clinical Trial Description, 2021

Table 67: Interleukin 2, Clinical Trial Description, 2021

Table 68: SKI-O-703, Clinical Trial Description, 2021

Table 69: Key Market Forecast Assumptions for Rozanolixizumab (UCB7665)

Table 70: Key Market Forecast Assumptions for Rilzabrutinib (PRN-1008)

Table 71: Key Market Forecast Assumptions for BAX930

Table 72: Key Market Forecast Assumptions for Efgartigimod (ARGX-113)

Table 73: Key Market Forecast Assumptions for Cablivi (caplacizumab)

Table 74: Key Market Forecast Assumptions for Tavalisse and Tavlesse (Fostamatinib)

Table 75: Key Market Forecast Assumptions for Doptelet (Avatrombopag)

Table 76: Key Market Forecast Assumptions for Nplate (Romiplostim)

Table 77: Key Market Forecast Assumptions for Mulpleta (lusutrombopag)

Table 78: Market Size of Thrombocytopenia in the 7MM in USD Million (2018–2030)

Table 79: Market Size of Thrombocytopenia by Current Therapies in the 7MM, in USD Million (2018–2030)

Table 80: Market Size of Thrombocytopenia by Potential Therapies in the 7MM, in USD Million (2018–2030)

Table 81: United States Market Size of Thrombocytopenia in USD Million (2018–2030)

Table 82: Market Size of Thrombocytopenia by Current Therapies in the US, in USD Million (2018–2030)

Table 83: Market Size of Thrombocytopenia by Potential Therapies in the US, in USD Million (2018–2030)

Table 84: Germany Market Size of Thrombocytopenia in USD Million (2018–2030)

Table 85: Market Size of Thrombocytopenia by Current Therapies in Germany, in USD Million (2018–2030)

Table 86: Market Size of Thrombocytopenia by Potential Therapies in Germany, in USD Million (2018–2030)

Table 87: France Market Size of Thrombocytopenia in USD Million (2018–2030)

Table 88: Market Size of Thrombocytopenia by Current Therapies in France, in USD Million (2018–2030)

Table 89: Market Size of Thrombocytopenia by Potential Therapies in France, in USD Million (2018–2030)

Table 90: Italy Market Size of Thrombocytopenia in USD Million (2018–2030)

Table 91: Market Size of Thrombocytopenia by Current Therapies in Italy, in USD Million (2018–2030)

Table 92: Market Size of Thrombocytopenia by Potential Therapies in Italy, in USD Million (2018–2030)

Table 93: Spain Market Size of Thrombocytopenia in USD Million (2018–2030)

Table 94: Market Size of Thrombocytopenia by Current Therapies in Spain, in USD Million (2018–2030)

Table 95: Market Size of Thrombocytopenia by Potential Therapies in Spain, in USD Million (2018–2030)

Table 96: United Kingdom Market Size of Thrombocytopenia in USD Million (2018–2030)

Table 97: Market Size of Thrombocytopenia by Current Therapies in the UK, in USD Million (2018–2030)

Table 98: Market Size of Thrombocytopenia by Potential Therapies in the UK, in USD Million (2018–2030)

Table 99: Japan Market Size of Thrombocytopenia in USD Million (2018–2030)

Table 100: Market Size of Thrombocytopenia by Current Therapies in Japan, in USD Million (2018–2030)

Table 101: Market Size of Thrombocytopenia by Potential Therapies in Japan, in USD Million (2018–2030)

List of Figures

Figure 1: Etiology of thrombocytopenia

Figure 2: Cellular pathogenic mechanisms in immune thrombocytopenia (ITP)

Figure 3: Thrombocytopenia: diagnostic algorithm starting with the complete blood count (CBC)

Figure 4: Diagnostic Algorithm to Confirm or Rule Out Heparin-Induced Thrombocytopenia (HIT) in Patients    

 Who Have Not Undergone Bypass Surgery

Figure 5: General approach and mechanism to the diagnosis of thrombocytopenia in liver disease

Figure 6: Flow chart for ADAMTS13 laboratory investigation in thrombotic thrombocytopenic purpura

Figure 7: Patient Journey

Figure 8: Total Prevalent Patient Population of Thrombocytopenia in the 7MM (2018–2030)

Figure 9: Prevalent Cases of Thrombotic Thrombocytopenic Purpura in the United States (2018–2030)

Figure 10: Prevalent Cases of Immune Thrombocytopenia in the United States (2018–2030)

Figure 11: Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in the United States (2018–2030)

Figure 12: Incident Cases of Chemotherapy-induced Thrombocytopenia in the United States (2018–2030)

Figure 13: Number of Cases of Heparin-induced Thrombocytopenia in the United States (2018–2030)

Figure 14: Total Cases of Thrombocytopenia in the United States (2018–2030)

Figure 15: Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Germany (2018–2030)

Figure 16: Prevalent Cases of Immune Thrombocytopenia in Germany (2018–2030)

Figure 17: Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Germany (2018–2030)

Figure 18: Incidence Cases of Chemotherapy-induced Thrombocytopenia in Germany (2018–2030)

Figure 19: Number of Cases of Heparin-induced Thrombocytopenia in Germany (2018–2030)

Figure 20: Total Cases of Thrombocytopenia in Germany (2018–2030)

Figure 21: Prevalent Cases of Thrombotic Thrombocytopenic Purpura in France (2018–2030)

Figure 22: Prevalent Cases of Immune Thrombocytopenia in France (2018–2030)

Figure 23: Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in France (2018–2030)

Figure 24: Incidence Cases of Chemotherapy-induced Thrombocytopenia in France (2018–2030)

Figure 25: Number of Cases of Heparin-induced Thrombocytopenia in France (2018–2030)

Figure 26: Total Cases of Thrombocytopenia in France (2018–2030)

Figure 27: Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Italy (2018–2030)

Figure 28: Prevalent Cases of Immune Thrombocytopenia in Italy (2018–2030)

Figure 29: Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Italy (2018–2030)

Figure 30: Incidence Cases of Chemotherapy-induced Thrombocytopenia in Italy (2018–2030)

Figure 31: Number of Cases of Heparin-induced Thrombocytopenia in Italy (2018–2030)

Figure 32: Total Cases of Thrombocytopenia in Italy (2018–2030)

Figure 33: Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Spain (2018–2030)

Figure 34: Prevalent Cases of Immune Thrombocytopenia in Spain (2018–2030)

Figure 35: Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Spain (2018–2030)

Figure 36: Incidence Cases of Chemotherapy-induced Thrombocytopenia in Spain (2018–2030)

Figure 37: Number of Cases of Heparin-induced Thrombocytopenia in Spain (2018–2030)

Figure 38: Total Cases of Thrombocytopenia in Spain (2018–2030)

Figure 39: Prevalent Cases of Thrombotic Thrombocytopenic Purpura in the UK (2018–2030)

Figure 40: Prevalent Cases of Immune Thrombocytopenia in the UK (2018–2030)

Figure 41: Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in the UK (2018–2030)

Figure 42: Incidence Cases of Chemotherapy-induced Thrombocytopenia in the UK (2018–2030)

Figure 43: Number of Cases of Heparin-induced Thrombocytopenia in the UK (2018–2030)

Figure 44: Total Cases of Thrombocytopenia in the UK (2018–2030)

Figure 45: Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Japan (2018–2030)

Figure 46: Prevalent Cases of Immune Thrombocytopenia in Japan (2018–2030)

Figure 47: Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Japan (2018–2030)

Figure 48: Incidence Cases of Chemotherapy-induced Thrombocytopenia in Japan (2018–2030)

Figure 49: Number of Cases of Heparin-induced Thrombocytopenia in Japan (2018–2030)

Figure 50: Total Cases of Thrombocytopenia in Japan (2018–2030)

Figure 51: Algorithm for the management of thrombocytopenia

Figure 52: Unmet needs for Thrombocytopenia

Figure 53: Market Size of Thrombocytopenia in the 7MM in USD Million (2018–2030)

Figure 54: Market Size of Thrombocytopenia by Current Therapies in the 7MM in USD Million (2018–2030)

Figure 55: Market Size of Thrombocytopenia by Potential Therapies in the 7MM in USD Million (2018–2030)

Figure 56: United States Market Size of Thrombocytopenia in USD Million (2018–2030)

Figure 57: Market Size of Thrombocytopenia by Current Therapies in the United States in USD Million (2018–2030)

Figure 58: Market Size of Thrombocytopenia by Potential Therapies in the United States in USD Million (2018–2030)

Figure 59: Germany Market Size of Thrombocytopenia in USD Million (2018–2030)

Figure 60: Market Size of Thrombocytopenia by Current Therapies in Germany in USD Million (2018–2030)

Figure 61: Market Size of Thrombocytopenia by Potential Therapies in Germany in USD Million (2018–2030)

Figure 62: France Market Size of Thrombocytopenia in USD Million (2018–2030)

Figure 63: Market Size of Thrombocytopenia by Current Therapies in France in USD Million (2018–2030)

Figure 64: Market Size of Thrombocytopenia by Potential Therapies in France in USD Million (2018–2030)

Figure 65: Italy Market Size of Thrombocytopenia in USD Million (2018–2030)

Figure 66: Market Size of Thrombocytopenia by Current Therapies in Italy in USD Million (2018–2030)

Figure 67: Market Size of Thrombocytopenia by Potential Therapies in Italy in USD Million (2018–2030)

Figure 68: Spain Market Size of Thrombocytopenia in USD Million (2018–2030)

Figure 69: Market Size of Thrombocytopenia by Current Therapies in Spain in USD Million (2018–2030)

Figure 70: Market Size of Thrombocytopenia by Potential Therapies in Spain in USD Million (2018–2030)

Figure 71: United Kingdom Market Size of Thrombocytopenia in USD Million (2018–2030)

Figure 72: Market Size of Thrombocytopenia by Current Therapies in the UK in USD Million (2018–2030)

Figure 73: Market Size of Thrombocytopenia by Potential Therapies in the United Kingdom in USD Million (2018–2030)

Figure 74: Japan Market Size of Thrombocytopenia in USD Million (2018–2030)

Figure 75: Market Size of Thrombocytopenia by Current Therapies in Japan in USD Million (2018–2030)

Figure 76: Market Size of Thrombocytopenia by Potential Therapies in Japan in USD Million (2018–2030)

Figure 77: Market Drivers

Figure 78: Market Barriers

Figure 79: SWOT Analysis of Thrombocytopenia

Sanofi (Ablynx)

Rigel Pharmaceuticals/Kissei Pharmaceutical

UCB Biopharma

Principia Biopharma

  • Tags:
  • Thrombocytopenia market
  • Thrombocytopenia market research
  • Thrombocytopenia market insight
  • Thrombocytopenia market trends
  • Thrombocytopenia market forecast
  • Thrombocytopenia market share
  • Thrombocytopenia pipeline drugs
  • Thrombocytopenia treatment algorit...
  • Thrombocytopenia drugs
  • Thrombocytopenia sales forecasting
  • Thrombocytopenia market size
  • Thrombocytopenia disease
  • Thrombocytopenia epidemiology
  • Thrombocytopenia

Forward to Friend

Need A Quote